FI20011187A - Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia - Google Patents
Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia Download PDFInfo
- Publication number
- FI20011187A FI20011187A FI20011187A FI20011187A FI20011187A FI 20011187 A FI20011187 A FI 20011187A FI 20011187 A FI20011187 A FI 20011187A FI 20011187 A FI20011187 A FI 20011187A FI 20011187 A FI20011187 A FI 20011187A
- Authority
- FI
- Finland
- Prior art keywords
- antigen
- new
- compositions intended
- protein
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73506991A | 1991-07-25 | 1991-07-25 | |
US73506991 | 1991-07-25 | ||
US9206193 | 1992-07-24 | ||
PCT/US1992/006193 WO1993001831A1 (en) | 1991-07-25 | 1992-07-24 | Induction of cytotoxic t-lymphocyte responses |
Publications (2)
Publication Number | Publication Date |
---|---|
FI20011187A true FI20011187A (fi) | 2001-06-05 |
FI109335B FI109335B (fi) | 2002-07-15 |
Family
ID=24954233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI940335A FI108114B (fi) | 1991-07-25 | 1994-01-24 | Menetelmä koostumuksen valmistamiseksi |
FI20011187A FI109335B (fi) | 1991-07-25 | 2001-06-05 | Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI940335A FI108114B (fi) | 1991-07-25 | 1994-01-24 | Menetelmä koostumuksen valmistamiseksi |
Country Status (27)
Country | Link |
---|---|
US (2) | US5585103A (fi) |
EP (1) | EP0596032B2 (fi) |
JP (1) | JP3939746B2 (fi) |
KR (1) | KR100198868B1 (fi) |
AT (1) | ATE166578T1 (fi) |
AU (1) | AU666127B2 (fi) |
BG (1) | BG62240B1 (fi) |
BR (1) | BR9206310A (fi) |
CA (1) | CA2113720A1 (fi) |
CZ (1) | CZ288048B6 (fi) |
DE (1) | DE69225710T3 (fi) |
DK (1) | DK0596032T4 (fi) |
ES (1) | ES2117052T5 (fi) |
FI (2) | FI108114B (fi) |
HU (2) | HU220295B (fi) |
IE (1) | IE922436A1 (fi) |
IL (1) | IL102639A (fi) |
MX (1) | MX9204376A (fi) |
NO (1) | NO317203B1 (fi) |
OA (1) | OA09880A (fi) |
PH (1) | PH30906A (fi) |
RO (1) | RO116459B1 (fi) |
RU (1) | RU2129439C1 (fi) |
SK (1) | SK282920B6 (fi) |
TW (1) | TW349867B (fi) |
WO (1) | WO1993001831A1 (fi) |
ZA (1) | ZA925614B (fi) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
AU6363094A (en) * | 1993-03-15 | 1994-10-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Peptide coated dendritic cells as immunogens |
GB9314623D0 (en) * | 1993-07-14 | 1993-08-25 | Nordion Int Inc | Localization and therapy with agents directed against prostate specific antigen in breast cancer |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AUPM446594A0 (en) * | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
US5820880A (en) * | 1995-06-07 | 1998-10-13 | The United States Of America As Represented By The Secretary Of The Army | Liposomal formulation |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
EP0991403B1 (en) * | 1997-01-30 | 2003-04-02 | Chiron Corporation | Use of microparticles with adsorbed antigen to stimulate immune responses |
EP0983086B1 (en) * | 1997-02-05 | 2007-08-29 | Jean-Claude Bystryn | pH-SENSITIVE LIPOSOMES AND OTHER TYPES OF ENCAPSULATED VACCINES CONTAINING IMMUNOMODULATORS, AND METHODS FOR MAKING AND USING SAME |
AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
US6632619B1 (en) * | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
DE69823347T2 (de) * | 1997-05-16 | 2005-05-12 | Alberta Research Council, Edmonton | Mikrofluidisches system und verfahren zu dessen betrieb |
WO1999011241A1 (en) | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
MY131805A (en) * | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
US6858386B1 (en) * | 1998-05-21 | 2005-02-22 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
US6949339B1 (en) * | 1998-05-21 | 2005-09-27 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging colon cancer |
CN1342085A (zh) * | 1998-10-30 | 2002-03-27 | 遗传研究所有限公司 | 通过p-选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化 |
WO2000028031A2 (en) * | 1998-11-10 | 2000-05-18 | Emory University | Mitogenic regulators |
US7198920B1 (en) * | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
US20050244434A1 (en) * | 1999-08-12 | 2005-11-03 | Cohen David I | Tat-based tolerogen compositions and methods of making and using same |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
CA2394914A1 (en) * | 1999-11-22 | 2001-05-31 | Susana Salceda | A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
US7238471B1 (en) | 1999-11-23 | 2007-07-03 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
US20020048777A1 (en) * | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
EP1292675A2 (en) * | 2000-05-26 | 2003-03-19 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
US7229623B1 (en) * | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
EP1343821A2 (en) | 2000-11-09 | 2003-09-17 | Immunolex Laboratories | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins |
US20070073047A1 (en) * | 2002-06-10 | 2007-03-29 | Biogen Idec Ma Inc. | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
EP1545575A4 (en) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE |
BR0315872A (pt) | 2002-10-29 | 2006-07-18 | Us Gov Health & Human Serv | Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso |
RU2541809C2 (ru) * | 2003-04-04 | 2015-02-20 | Зоетис Пи ЛЛК | Микрофлюидизированные эмульсии "масло в воде" и композиции вакцины |
JP2006528647A (ja) * | 2003-07-24 | 2006-12-21 | メリアル リミテッド | 新規ワクチン製剤 |
ES2423663T3 (es) | 2005-08-08 | 2013-09-23 | Oregon Health And Science University | Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas |
US20100130425A1 (en) | 2005-09-09 | 2010-05-27 | Oregon Health & Science University | Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia |
EP1994409A2 (en) | 2006-03-14 | 2008-11-26 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
EP2019684A4 (en) | 2006-04-20 | 2009-08-26 | Jackson H M Found Military Med | METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN PROTEIN TYPE 1 |
AU2007354917B2 (en) | 2006-09-26 | 2013-06-06 | Access To Advanced Health Institute | Vaccine composition containing synthetic adjuvant |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
TWI441648B (zh) | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Foxp3胜肽疫苗 |
AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
RU2499606C2 (ru) * | 2007-10-18 | 2013-11-27 | Бавэариан Нордик Инк. | Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты |
US9005631B2 (en) | 2008-08-04 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
ES2432863T3 (es) | 2009-03-23 | 2013-12-05 | Pin Pharma, Inc. | Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH |
CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
CA2776922A1 (en) | 2009-10-07 | 2011-04-14 | Uvic Industry Partnerships Inc. | Vaccines comprising heat-sensitive transgenes |
US9181306B2 (en) | 2009-10-16 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
US8961989B2 (en) | 2009-11-20 | 2015-02-24 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
AU2012267786B2 (en) | 2011-06-10 | 2017-08-03 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
ES2855110T3 (es) | 2011-07-18 | 2021-09-23 | The Us Secretary Department Of Health And Human Services National Institutes Of Health | Métodos y composiciones para la inhibición de una patología asociada a poliomavirus |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
US9566329B2 (en) | 2012-04-06 | 2017-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live, attenuated rubella vector to express vaccine antigens |
SI2850431T1 (en) | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccine against HSV-2 |
NZ702146A (en) | 2012-06-06 | 2016-11-25 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
CA2888367A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
EA032326B1 (ru) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Монотерапия gla для применения в лечении рака |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
CA2926221A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
DK3079716T3 (da) | 2013-12-13 | 2019-08-19 | Us Health | Multiepitop-tarp-peptidvaccine og anvendelser deraf. |
WO2015095770A1 (en) | 2013-12-20 | 2015-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic jc polyomavirus compositions and methods of use |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10550164B2 (en) | 2015-08-03 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use |
JP6843970B2 (ja) | 2016-05-10 | 2021-03-17 | ナジット テクノロジーズ, インコーポレイテッド | 二重酸化プロセスを使用して病原体を不活性化し高度免疫原性不活性化ワクチンを産生すること |
EP3703745B1 (en) | 2017-11-04 | 2024-04-10 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
EP3891170A4 (en) | 2018-12-04 | 2022-12-07 | The Rockefeller University | IMMUNOGENS FOR HIV VACCINE |
US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3083142A (en) * | 1958-02-27 | 1963-03-26 | Glaxo Group Ltd | Improved swine erysipelas vaccine |
US3790665A (en) * | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
US4117113A (en) * | 1974-06-25 | 1978-09-26 | National Research Development Corporation | Immunological preparations |
US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
ATE136468T1 (de) * | 1986-10-20 | 1996-04-15 | Chiron Corp | Impfstoff zur behandlung von hsv |
US4778784A (en) * | 1987-01-07 | 1988-10-18 | Baylor College Of Medicine | Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus |
US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
JPH0832638B2 (ja) * | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
AU1025692A (en) * | 1991-02-06 | 1992-08-13 | Ciba-Geigy Ag | Novel chimeric antiidiotypic monoclonal antibodies |
-
1992
- 1992-07-24 DE DE69225710T patent/DE69225710T3/de not_active Expired - Fee Related
- 1992-07-24 IL IL102639A patent/IL102639A/xx not_active IP Right Cessation
- 1992-07-24 RU RU94038046/14A patent/RU2129439C1/ru not_active IP Right Cessation
- 1992-07-24 IE IE243692A patent/IE922436A1/en not_active IP Right Cessation
- 1992-07-24 PH PH44711A patent/PH30906A/en unknown
- 1992-07-24 MX MX9204376A patent/MX9204376A/es not_active IP Right Cessation
- 1992-07-24 JP JP50307193A patent/JP3939746B2/ja not_active Expired - Fee Related
- 1992-07-24 HU HU9400202A patent/HU220295B/hu not_active IP Right Cessation
- 1992-07-24 EP EP92917479A patent/EP0596032B2/en not_active Expired - Lifetime
- 1992-07-24 CZ CZ1994150A patent/CZ288048B6/cs not_active IP Right Cessation
- 1992-07-24 KR KR1019940700218A patent/KR100198868B1/ko not_active IP Right Cessation
- 1992-07-24 AT AT92917479T patent/ATE166578T1/de not_active IP Right Cessation
- 1992-07-24 DK DK92917479T patent/DK0596032T4/da active
- 1992-07-24 CA CA002113720A patent/CA2113720A1/en not_active Abandoned
- 1992-07-24 ES ES92917479T patent/ES2117052T5/es not_active Expired - Lifetime
- 1992-07-24 AU AU24338/92A patent/AU666127B2/en not_active Ceased
- 1992-07-24 BR BR9206310A patent/BR9206310A/pt not_active Application Discontinuation
- 1992-07-24 RO RO94-00094A patent/RO116459B1/ro unknown
- 1992-07-24 US US07/919,787 patent/US5585103A/en not_active Expired - Lifetime
- 1992-07-24 WO PCT/US1992/006193 patent/WO1993001831A1/en active IP Right Grant
- 1992-07-24 SK SK89-94A patent/SK282920B6/sk unknown
- 1992-07-27 ZA ZA925614A patent/ZA925614B/xx unknown
- 1992-08-27 TW TW081105966A patent/TW349867B/zh not_active IP Right Cessation
-
1994
- 1994-01-21 NO NO19940218A patent/NO317203B1/no unknown
- 1994-01-24 FI FI940335A patent/FI108114B/fi active
- 1994-01-24 BG BG98410A patent/BG62240B1/bg unknown
- 1994-01-24 OA OA60461A patent/OA09880A/en unknown
-
1995
- 1995-05-24 US US08/449,728 patent/US6270769B1/en not_active Expired - Fee Related
- 1995-06-22 HU HU95P/P00339P patent/HU211299A9/hu unknown
-
2001
- 2001-06-05 FI FI20011187A patent/FI109335B/fi active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20011187A (fi) | Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia | |
ES2123547T3 (es) | Formulaciones, metodos y dispositivos contraceptivos transdermicos. | |
MD1586G2 (ro) | Inducere a unui răspuns citotoxic T-limfocitar | |
MX9302982A (es) | Composicion de vacuna que incluye componente de vacuna de la hepatitis b, para el tratamiento de infecciones por hepatitis b. | |
FI944676A0 (fi) | Rokotteita, jotka sisältävät ionisoitumattomia pinta-aktiivisten aineiden vesikkeleitä | |
DE60125797D1 (de) | Impfstoffzusammesetzung | |
DE69131709D1 (de) | Liposomen enthaltende impfstoffzusammensetzungen | |
MA23344A1 (fr) | Nouvelles compositions d'emulsions | |
BR0210772A (pt) | Usos de um anticorpo anti-hla, e de uma composição de soro de cabra | |
KR970032889A (ko) | B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: BIOGEN IDEC INC. Free format text: BIOGEN IDEC INC. |